Sanofi, “We’ll start 2 new Phase III clinical trials of Hanmi’s efpeglenatide this year”

Hanmi Pharm(CEO Sae-Chang Kwon, Jong-Soo Woo) will conduct 2 more new Phase III clinical trials to increase the value of efpeglenatide, a new antidiabetic biologic.

A partnering company of Hanmi Pharm, Sanofi announced this at its 2017 4^th quarter performance report on the 7^th(local time). Sanofi also announced a plan to apply approval of efpeglenatide in the U.S. FDA in 2021 based on the Phas...